Can ventilatory strategies in COVID-19 have an impact on outcomes?

Dr Peter B Sherren1*, Dr Luigi Camporota1, Mr Barnaby Sanderson1, Dr Andrew Jones1, Dr Manu Shankar-Hari1, Dr Chris IS Meadows1, Dr Nicholas Barrett1, Dr Marlies Ostermann1, Prof Nicholas Hart1.

1 Department of Critical Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

* Corresponding author: Dr PB Sherren, Consultant, Department of Critical Care Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. Email: Peter.Sherren@GSTT.nhs.uk.

**Word count:** 1017

**Disclaimers:** The views expressed in the submitted article are his or her own and not an official position of the institution or funder.

**Disclosure of relationships and activities:** The authors declare that they have no conflicts of interest.

**Authors approval:** All authors have reviewed and approved the final manuscript.

**Funding/Support:** Dr Shankar-Hari is supported by National Institute for Health Research Clinician Scientist Award CS-2016-16-011. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health and Social Care.

**Ethical approval:** The study had institutional approval (institutional research governance reference number: 10796) and qualified as a service evaluation as defined by the UK NHS Health Research Authority and therefore did not require review by the Research Ethics
Committee (http://www.hra.nhs.uk) and had waiver of individual informed consent, when used without breach of privacy or anonymity.
Abstract: The rapidly evolving understanding of Coronavirus Disease 2019 (COVID-19) respiratory failure pathogenesis, limited disease-specific evidence and demand-resource imbalances have posed significant challenges for intensive care clinicians. In this single-centre retrospective cohort study we describe the outcomes of COVID-19 patients admitted to Guy’s and St. Thomas’ NHS Foundation Trust (GSTT) critical care service. Patients were managed according to a local respiratory failure management pathway that was predicated on timely invasive ventilation when indicated and tailored ventilatory strategies according to pulmonary mechanics. Between 2\textsuperscript{nd} March and 25\textsuperscript{th} May 2020 GSTT critical care service admitted 316 patients with confirmed COVID-19. Of the 201 patients admitted directly through the Emergency Department with a completed critical care outcome, 71.1% survived to critical care discharge. These favourable outcomes may serve to inform the wider debate on the optimal ventilatory management in COVID-19.
To the Editor:

Acute hypoxemic respiratory failure (AHRF) is the commonest organ dysfunction that results in critical care admission with Coronavirus Disease 2019 (COVID-19). Clinically, it is debatable whether the pathophysiology of AHRF in COVID-19 resembles Acute Respiratory Distress Syndrome (ARDS), as this is influenced by the timing of presentation and may be affected by the treatments received.[1] The uncertainties generated by this new disease have engendered a debate on the optimal strategy for respiratory support and highlighted the need for data to help design clinical trials. However, in the context of a pandemic, institutions needed to develop pragmatic clinical pathways to meet the excess critical care demand and consider how best to use the available local resources - such as ventilators, staffing and oxygen supplies.

The objective of this study was to evaluate the impact of a locally derived respiratory failure management pathway on the outcomes of critically ill COVID-19 patients admitted to a high volume severe respiratory failure centre in the United Kingdom (UK).

Methods

This was a retrospective single-centre cohort study of all RT-PCR confirmed COVID-19 patients admitted to the critical care service at Guy’s and St. Thomas’ NHS Foundation Trust (GSTT) from 2nd March to 25th May 2020. GSTT, located in central London, is one of six nationally-commissioned severe respiratory failure and extracorporeal membrane oxygenation (ECMO) centres. In response to the pandemic, the service increased its critical care capacity in a phased manner up to 187 beds capable of invasive ventilation and developed a respiratory failure management pathway for COVID-19 (Figure 1), based on published literature as of 20th March 2020 and discussions with international experts.
Briefly, after an initial triage assessment performed on oxygen alone and an assessment of the work of breathing, patients were considered for a time-limited trial of awake proning or non-invasive respiratory support, or otherwise for endotracheal intubation. The overarching objective was the avoidance of delayed invasive mechanical ventilation in patients with increased work of breathing or severe hypoxemia. Subsequent ventilation and positive end expiratory pressure (PEEP) selection were based on categories of static compliance and driving pressure. Preference was given to prone position rather than higher PEEP. This is consistent with emerging phenotypes identified using international observational data.[1]

The definition of a priori parameters based on a pathophysiological construct, together with a substantial increase in our resources, allowed us to provide the required respiratory support for an individual patient, according to an egalitarian, rather than utilitarian perspective.

The primary outcome was critical care mortality in patients admitted directly to GSTT. Given the wide range of mortality reported in the literature, it is useful to consider our single-centre outcomes in the context of the UK data reported by Intensive Care National Audit and Research Centre (ICNARC).

Results

During the study period, our critical care service admitted 316 confirmed COVID-19 patients, including 52 mobile ECMO retrievals and 51 non-ECMO critical care transfers from other institutions (Figure 2).

A total of 213 COVID-19 patients were admitted directly to our critical care service through our Emergency Department, and 201 patients had a completed critical care discharge outcome. The median [IQR] age of patients was 58 [49,66] years, 66.7% were men, 52.2% were from Black, Asian and Minority Ethnic (BAME) groups, and the median [IQR] Acute
Physiology And Chronic Health Evaluation (APACHE) II score was 14 [11,18]. 166 (82.6%) patients required invasive ventilation and 61 (30.3%) non-invasive respiratory support. Of the 61 patients who received non-invasive support, 41 (67.2%) received it only following extubation. Of the 48 patients coded as receiving ‘High flow nasal oxygen’, 28 (58.3%) received it primarily for humidification purposes with flow rates ≤ 15 litres-per-minute. Only one patient originally admitted to GSTT required ECMO initiation for AHRF due to a concurrent massive pulmonary embolism. Our critical care mortality was 28.9%.

**Discussion**

This is one of the largest single-centre studies describing outcomes of critically ill COVID-19 patients managed according to a local respiratory failure management pathway. The survival to critical care discharge of 71.1% provides reassurance that a strategy predicated on timely invasive ventilation and personalised ventilatory strategies can confer favourable outcomes. This strategy and outcomes are similar to the one adopted and described by Ziehr et al, where in a smaller cohort of 66 patients, the authors report a mortality of 16.7%.[2] When comparing to the contemporaneous ICNARC report of 9,026 COVID-19 patients admitted to critical care in the UK, our cohort had comparable baseline characteristics (age, sex, BMI and APACHE II scores) but with higher rates of advanced respiratory support (82.6% versus 72.5%), lower use of basic respiratory support (30.3% versus 63.3%) and a lower mortality (28.9% versus 44.3%).[3]

COVID-19 is an inflammatory vasculopathy that is initially associated with minimal parenchymal edema and atelectasis but significant pulmonary shunt, dead space and hypoxemia.[1] As lung edema increases, use of non-invasive positive pressure ventilation may improve oxygenation. However, unless the work of breathing and lung shear stress are reduced, there is concerns that prolonged non-invasive support can mask ongoing patient
self-inflicted lung injury (P-SILI) resulting in progressive inflammation and potentially refractory hypoxemia.[4] This possibility was recognized and reported by intensive care experts in Wuhan, China.[5] Whilst difficult to estimate the impact of the individual components of our management pathway, we postulate that avoiding delayed invasive mechanical ventilation and adapting mechanical ventilation to pulmonary mechanics can affect outcome in COVID-19. This may explain the significant mortality difference observed between our cohort and national data, and is congruent with the established evidence base suggesting high failure rates and excess mortality observed in patients receiving non-invasive ventilation in moderate-to-severe de novo AHRF.[6-9]

This study has a number of limitations. With a single-centre retrospective study it is difficult to adjust for unmeasured confounders, including thresholds for critical care admission and adjunctive management strategies beyond ventilation. When comparing local data to the national ICNARC data, the authors accept that confounding by indication influences any inference.

Despite these limitations, the strategy and outcomes reported may serve to inform the wider debate on the optimal ventilatory management of COVID-19. Further prospective clinical trials comparing time-limited non-invasive respiratory support with standard care may help guide such debate.[10]
References:

1. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? *Intensive Care Med.* 2020 Apr 14. [Epub ahead of print].

2. Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff B, et al. Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study [published online ahead of print, 2020 Apr 29]. *Am J Respir Crit Care Med.* 2020;10.1164/rccm.202004-1163LE.

3. Intensive Care National Audit and Research Network. ICNARC report on COVID-19 in critical care. https://www.icnarc.org/DataServices/Attachments/Download/96b455be-059e-ea11-9126-00505601089b. Date last updated: May 22, 2020. Date last accessed: May 25, 2020.

4. Tonelli R, Fantini R, Tabbi L, Castaniere I, Pisani L, Pellegrino MR, et al. Inspiratory Effort Assessment by Esophageal Manometry Early Predicts Noninvasive Ventilation Outcome in de novo Respiratory Failure: A Pilot Study. *Am J Respir Crit Care Med.* Epub 2020 Apr 23.

5. Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, et al. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Ann. Intensive Care 10, 73 (2020).

6. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study. *Am J Respir Crit Care Med.* 2017 Jan 1;195(1):67-77.
7. Rodríguez A, Ferri C, Martin-Loeches I, Díaz E, Masclans JR, Gordo F, et al. Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection. *Respir Care.* 2017 Oct;62(10):1307-1315. Epub 2017 Jul 11.

8. Thille AW, Contou D, Fragnoli C, Córdoba-Izquierdo A, Boissier F, Brun-Buisson C. Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors. *Crit Care.* 2013;17(6):R269.

9. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. *Intensive Care Med.* 2012;38(3):458-466.

10. International Standard Randomised Controlled Trial Number. RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care. [http://www.isrctn.com/ISRCTN16912075](http://www.isrctn.com/ISRCTN16912075). Date last updated: April 15, 2020. Date last accessed: May 28, 2020.
Figure 1. Guy’s and St. Thomas’ NHS Foundation Trust suggested management of respiratory failure in Coronavirus Disease 2019 (COVID-19). RR - Respiratory rate, NRBM - Non-Rebreather Mask, CRT - Critical Care Response Team, MERIT - Mobile Emergency Response Intubation Team, HCID - High Consequence Infectious Disease, HDU - High Dependency Unit, ED - Emergency Department, MV - Minute ventilation, PEEP - Positive End Expiratory Pressure, Vt - Tidal Volume, PBW - Predicted Body Weight, RM - Recruitment Manoeuvre and ECMO - Extracorporeal Membrane Oxygenation.

Management of Respiratory Failure

Suspected or Confirmed COVID-19

- Titrating FiO₂ to Target SpO₂ (92-96% for the majority of patients)

**Ward**

- SpO₂ in target: with FiO₂ ≤0.4 and RR ≤ 24/min

**CRT Review**

- SpO₂ in target: with FiO₂ > 0.6 or RR ≥ 25/min and no call of escalation

**Work of Breathing**

- **Low**
  - Intubation + MV (Call MERIT)
  - Volume Control ventilation
    - Tidal Volume: 8 ml/kg PBW
    - PEEP: 8 cmH₂O
    - RR - initially to ETCO₂: 4.5 kPa

- **High**
  - Is driving pressure <15 cmH₂O?
  - No
    - Reduce Vt to 6 ml/Kg PBW
  - Yes
    - Keep Vt at 8 ml/Kg PBW

- SpO₂ <92% with FiO₂ ≥ 0.7
  - Compliance ≥ 40 ml/cmH₂O
  - No
    - Neuro-Muscular Blockade
      - Increase PEEP in 2 cmH₂O steps (up to 15 cmH₂O)
      - Consider RM (40 cmH₂O x 10 s)
      - SpO₂ <92% with FiO₂ ≥0.7
    - Prone Position
      - Hypoxaemia refractory to “higher PEEP” and “prone position” for ≥ 6 hours (or sooner if life-threatening hypoxaemia or hypercapnia)
  - Yes
    - Echo
      - As soon as feasible
    - Prone Position
      - Ventilatory settings as above
      - SpO₂ <92% with FiO₂ ≥ 0.7
    - Trial of Pulmonary vasodilators
      - (feasible and available)

- SpO₂ <92% with FiO₂ ≥ 0.7
  - Discuss with ECMO Consultant
    - ECMO candidate?
  - No
    - Review Targets and Strategy
  - Yes
    - VV-ECMO
Figure 2. Flowchart of the 316 patients admitted to Guy’s and St. Thomas’ NHS Foundation Trust (GSTT) Critical Care with confirmed Coronavirus Disease 2019 (COVID-19). ECMO - Extracorporeal Membrane Oxygenation, BMI - Body Mass Index, BAME - Black, Asian and Minority Ethnic, APACHE - Acute Physiology And Chronic Health Evaluation, NIV - Non-Invasive Ventilation, and HFNO - High Flow Nasal Oxygen. *Of the 48 patients coded as receiving ‘High flow nasal oxygen’, 28 (58.3%) received it primarily for humidification purposes with flow rates ≤ 15 litres-per-minute.